source
- PepGen's Phase 2 DM1 Data Show 46% Average Splicing Correction, Shares Jump 163%PepGen reported results from the 10 mg/kg multiple‑ascending‑dose cohort of its ongoing Phase 2 Freedom2‑DM1 trial, testing PGN‑EDODM1, an oligonucleotide designed to correct the molecular defect i…
- London startup Oyster Therapeutics raises $60M to develop oral tau degraders for Alzheimer’sOyster Therapeutics, a London‑based biotech, announced it has closed a $60 million Series A‑2 financing round. The round was led by 4BIO Capital, a life‑science venture capital firm, with addition…